MedTrace Logo

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

NCT07562087 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2026-05-20

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.

Conditions

Interventions

DRUG

TP-05 (lotilaner) Low Dose

TP05 administered orally at the protocol-defined preventative dose.

DRUG

TP-05 (lotilaner) High Dose

TP05 administered orally at the protocol-defined preventative dose.

DRUG

Placebo

Matching placebo administered orally according to the same dosing schedule as TP05.

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Tarsus Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2027-10-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07562087 on ClinicalTrials.gov